Every instrument vendor, every kit company, and every informatics platform now claims to be “AI-powered.” Which means the phrase has stopped doing any commercial work for you. Technical buyers have heard it enough times that it now triggers skepticism instead of interest.
That skepticism is earned. AI is genuinely embedded in this market: augmenting genomics and proteomics data analysis, helping identify molecular targets, enhancing diagnostic imaging, automating repetitive lab tasks. It’s real infrastructure. But a label without a specific, demonstrable function, and without validated evidence behind it, is exactly the kind of claim that erodes trust the first time a buyer asks for the data.
If your product has real AI capability, you have an advantage. If your sales and marketing language can’t survive a skeptical scientist asking “show me,” you have already lost the customer.
Two different risk categories, treated as one
There’s an important distinction most companies miss: AI as an internal commercial tool and AI as a product claim carry completely different risk profiles. You can use AI aggressively inside your own CRM for lead scoring, content drafting, and pipeline analysis. That’s low risk and fast ROI.
Claiming your instrument uses AI to improve diagnostic accuracy is a different category entirely. That claim needs a documented source, technical or regulatory sign-off, and consistent language across sales, marketing, and technical support, the same discipline you already apply to a sensitivity or yield specification claim.
PSG Life Sciences works across the informatics and digital technologies market, bioinformatics platforms, cloud-based analytics, AI- and ML-driven decision support tools, and the CRM and procurement systems that connect them. We help you use AI credibly in both directions: inside your commercial operation, and in how you talk about your product.
Where PSG Life Sciences fits
Need your AI-enabled product positioned with evidence instead of hype? Our Start solution builds the ideal customer profile and messaging for each specific buyer (bioinformatics teams, diagnostic labs, discovery scientists) tailored to the evidence each one actually expects before they believe an AI claim.
Want AI working inside your own sales and marketing operation? HubSpot Life Sciences Pro puts AI-enabled lead scoring, data enrichment, and content drafting to work inside a CRM built for life science sales cycles, so you’re using the technology you sell, not just selling it.
Growing past your early adopter stage and need a real pipeline that generates consistent revenue to match? Our Grow solution builds the demand generation and conversion tracking system that shows which AI-related claims are actually driving qualified pipeline, not just impressions.
What we actually build for AI-enabled tool and informatics companies
- Buyer-specific AI messaging: bioinformatics teams, diagnostic labs, and discovery scientists each expect different proof before they trust an AI claim
- AI-enabled CRM operations: lead scoring, segmentation, campaign analysis, and dormant account reactivation built on your own customer and product data
- Content built on approved technical documentation, not generic AI capability claims that could describe any competitor’s product
- Pipeline tracking that separates genuine AI-driven interest from traffic generated by buzzword-chasing content
A direct question worth asking yourself
If a skeptical scientific buyer asked you to back up your AI claim with the underlying validation data right now, could your team produce it in the meeting, or would there be an awkward pause while someone goes to check?
Ready to make your AI claims hold up under scrutiny?
PSG Life Sciences is a HubSpot Gold partner and fractional commercialization firm working exclusively with biotech, life science, and diagnostic product companies, including the bioinformatics and AI-driven decision support tools this market depends on. We build the credible positioning and AI-enabled CRM systems described above as implemented client work, not theory.